Allergies News and Research

Latest Allergies News and Research

American beautyberry leaf extract boosts antibiotic's activity against 'superbug'

Scientists discovered a compound in the leaves of a common shrub, the American beautyberry, that boosts an antibiotic's activity against antibiotic-resistant staph bacteria.

16 Jul 2020

KHN’s ‘What the Health?’: The Trump administration’s war on Fauci

Not only does the Trump administration lack a comprehensive plan for addressing the ongoing coronavirus pandemic, it spent much of the past week working to undercut one of the nation’s most trusted scientists, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

16 Jul 2020

A coronavirus vaccine: Where does it stand?

More than four months into the coronavirus pandemic, how close are the U.S. and the world to a safe and effective vaccine? Scientists say they see steady progress and are expressing cautious optimism that a vaccine could be ready by spring.

16 Jul 2020

New immune profiles could help predict disease trajectory in severe COVID-19 patients

Researchers from the Penn Institute of Immunology discovered three distinct immune responses to the SARS-CoV2 infection that could help predict the trajectory of disease in severe COVID-19 patients and may ultimately inform how to best treat them.

15 Jul 2020

Buck researchers investigate ketone bodies as possible therapeutic against COVID-19

Given the disproportionate impact that COVID-19 has on older adults in terms of death and lasting disability, and the impact of common aging-related comorbidities like diabetes and cardiovascular disease, Buck Institute professor and practicing geriatrician John Newman, MD, PhD, can make a compelling argument that those infected with the SARS-CoV2 virus are suffering from an aging-related disease, no matter how old they are when they get infected.

15 Jul 2020

Moderna vaccine induces robust immune response against SARS-CoV-2

The race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on, and one of the potential candidates shows promise in inducing an immune response.

15 Jul 2020

Georgia State professor receives federal funding to study unique features of Ebola, Marburg viruses

Dr. Christopher Basler, professor and director of the Center for Microbial Pathogenesis in the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.94 million federal grant to study unique features of Ebola and Marburg viruses that control how the virus family expresses its genes and escapes immune responses.

15 Jul 2020

ATS releases new practice guideline on treating tobacco dependence in adult smokers

Smoking cessation initiatives notwithstanding, along with provocative public health campaigns and clinical guidance, quitting tobacco has remained elusive for many smokers.

15 Jul 2020

Experimental vaccine induces neutralizing antibodies against SARS-CoV-2

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine.

15 Jul 2020

COVID-19 may have an impact on the central nervous system of patients

Depressed mood or anxiety exhibited in COVID-19 patients may possibly be a sign the virus affects the central nervous system, according to an international study led by a University of Cincinnati College of Medicine researcher.

14 Jul 2020

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

13 Jul 2020

New guidance published for research on HIV, co-infections in pregnancy

Pregnant women are among those most in need of safe and effective preventives and treatments for HIV and co-infections. Yet because they are commonly excluded from research, they are among the least likely to have robust, timely evidence to inform decisions around the use of medications.

12 Jul 2020

New mutation in common subtype of influenza virus helps evade immune response

Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.

12 Jul 2020

COPD has substantial physical and psychosocial impact on younger patients, survey reveals

Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstructive Pulmonary Disease.

10 Jul 2020

Volunteers can now register for coronavirus disease vaccine trials

In an attempt to recruit many volunteers, the National Institute of Allergy and Infectious Diseases (NIAID) has established a new clinical COVID-19 Prevention Trials Network (COVPN) that aims to enroll thousands of volunteers to test various investigational vaccines against the SARS-CoV-2 infection.

10 Jul 2020

Expansion stress promotes aggressive tumor cell growth in breast cancer

Expansion stress can have an alarming impact on breast cancer cells by creating conditions that could lead to dangerous acceleration of the disease, an interdisciplinary team of University of Alabama at Birmingham researchers has found.

9 Jul 2020

Proximity to natural environments benefits formula-fed babies' gut microbiome

Living close to natural green space can mitigate some of the changes in infant gut bacteria associated with formula feeding, according to new research published in the journal Environment International.

9 Jul 2020

UofSC researchers win NIH grant to develop data-driven system to track COVID-19

University of South Carolina researchers from its Big Data Health Science Center initiative have received $1.25 million in grant funding from the NIH National Institute of Allergy and Infectious Diseases (NIAID) to develop a data-driven system to track COVID-19 in South Carolina.

8 Jul 2020

NIH establishes a unified clinical trial network for testing COVID-19 vaccines

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has established a new clinical trials network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.

8 Jul 2020